Fluconazole    (DrugBank: Fluconazole)

2 diseases
IDDisease name (Link within this page)Number of trials
96Crohn disease4
225Congenital nephrogenic diabetes insipidus1

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 2,209 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03476317
(ClinicalTrials.gov)
July 12, 20188/1/2018Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's DiseaseAn Open-Label Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's DiseaseCrohn DiseaseDrug: Vancomycin;Drug: Neomycin;Drug: Ciprofloxacin;Drug: Polyethylene Glycol 3350;Drug: FluconazoleChildren's Hospital of PhiladelphiaUniversity of Pennsylvania;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruiting6 YearsN/AAll60Phase 2United States
2NCT02765256
(ClinicalTrials.gov)
August 20162/5/2016Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's DiseaseFundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's DiseaseCrohn's DiseaseDrug: Fluconazole;Drug: Vancomycin;Drug: Neomycin;Drug: Ciprofloxacin;Drug: Polyethylene Glycol 3350;Drug: Promethazine;Drug: Fluconazole placeboUniversity of PennsylvaniaChildren's Hospital of Philadelphia;Crohn's and Colitis FoundationCompleted18 Years75 YearsAll8Phase 2United States
3EUCTR2008-003167-39-BE
(EUCTR)
17/09/200828/08/2008Effet du fluconazole sur le taux d'anticorps anti-Saccharomyces cerevisiae (ASCSA) après résection chirurgicale pour maladie de Crohn.Effet du fluconazole sur le taux d'anticorps anti-Saccharomyces cerevisiae (ASCSA) après résection chirurgicale pour maladie de Crohn. Crohn' disease
MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease
Trade Name: diflucan
INN or Proposed INN: FLUCONAZOLE
Cliniques Universitaires Saint LucNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Belgium
4NCT02997059
(ClinicalTrials.gov)
July 200814/12/2016Effect of Fluconazole on the Levels of ASCA After Surgical Resection for Crohn's Disease.Effect of Fluconazole on the Levels of Anti-Saccharomyces Cerevisiae Antibodies (ASCA) After Surgical Resection for Crohn's Disease. Multicenter, Randomized, and Controlled in Two Parallel Groups Versus PlaceboCrohn's Disease AggravatedDrug: Fluconazole;Other: PlaceboUniversity Hospital, LilleMinistry of Health, FranceTerminated18 YearsN/ABoth35Phase 2France

225. Congenital nephrogenic diabetes insipidus    [ 12 clinical trials,   45 drugs,   (DrugBank: 17 drugs),   30 drug target genes,   63 drug target pathways]
Searched query = "Congenital nephrogenic diabetes insipidus", "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 12 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-002204-38-DK
(EUCTR)
24/11/202007/05/2020Treatment of the genetic disease nephrogenic diabetes insipidus with the antifungal drug FluconazoleTreatment of congenital nephrogenic diabetes insipidus with fluconazole, an antifungal medication Nephrogenic diabetes insipidus
MedDRA version: 21.0;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
INN or Proposed INN: Fluconazole
Other descriptive name: FLUCONAZOLE
Claus BistrupNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
10Phase 2Denmark